Oncopeptides is a global biotech company, founded in Sweden, focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.
CEO Jakob Lindberg
Science is leading the way
"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO
Multiple myeloma
Multiple myeloma is a cancer of the bone marrow that results in production of abnormal blood plasma cells. The disease is linked to substantial morbidity and mortality, and there is currently no cure. Patients being treated for multiple myeloma will experience symptom free periods, but they will relapse as the disease develops resistance to the treatment.
Read the global press releases
Below is a link to our global press releases from Oncopeptides AB (publ). This link takes you to our global website.
